CheckMate 227: Nivolumab plus Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

被引：0
|
作者：
Mathias, C. [1 ]
Reck, M. [2 ]
Hellmann, M. [3 ]
Ramalingam, S. [4 ]
Brahmer, J. [5 ]
O'Byrne, K. [6 ]
Bhagavatheeswaran, P. [7 ]
Nathan, F. [7 ]
Borghaei, H. [8 ]
Paz-Ares, L. [9 ,10 ]
机构：
[1] Nucleo Oncol Bahia, Salvador, BA, Brazil
[2] German Ctr Lung Res DZL, Lung Clin Grosshansdorf, ARCN, Grosshansdorf, Germany
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Princess Alexandra Hosp Brisbane, Brisbane, Qld, Australia
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[9] Univ Complutense, CNIO, Hosp Univ Doce Octubre, Madrid, Spain
[10] CiberOnc, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 09期
关键词：
tumor mutational burden; patient-reported outcomes; nivolumab; NSCLC;
D O I：
10.1016/j.jtho.2018.07.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2
引用
收藏
页码：S152 / S153
页数：2
相关论文
共 50 条
  • [41] CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
    Schenker, Michael
    Burotto, Mauricio
    Richardet, Martin
    Ciuleanu, Tudor
    Goncalves, Anthony
    Steeghs, Neeltje
    Schoffski, Patrick
    Ascierto, Paolo A.
    Maio, Michele
    Lugowska, Iwona
    Lupinacci, Lorena
    Leary, Alexandra
    Delord, Jean-Pierre
    Grasselli, Julieta
    Tan, David S.
    Friedmann, Jennifer E.
    Vuky, Jacqueline
    Tschaika, Marina
    Slepetis, Ruta
    Kollia, Georgia D.
    Pacius, Misena
    Huang, Ning
    Doshi, Parul
    Baden, Jonathan
    Di Nicola, Massimo
    CANCER RESEARCH, 2022, 82 (12)
  • [42] First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
    Ready, Neal
    Hellmann, Matthew D.
    Awad, Mark M.
    Otterson, Gregory A.
    Gutierrez, Martin
    Gainor, Justin F.
    Borghaei, Hossein
    Jolivet, Jacques
    Horn, Leora
    Mates, Mihaela
    Brahmer, Julie
    Rabinowitz, Ian
    Reddy, Pavan S.
    Chesney, Jason
    Orcutt, James
    Spigel, David R.
    Reck, Martin
    O'Byrne, Kenneth John
    Paz-Ares, Luis
    Hu, Wenhua
    Zerba, Kim
    Li, Xuemei
    Lestini, Brian
    Geese, William J.
    Szustakowski, Joseph D.
    Green, George
    Chang, Han
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) : 992 - +
  • [43] Nivolumab (NIVO) plus ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1
    Ramalingam, S. S.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. -S.
    Schenker, M.
    Caro, R. B.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Provencio, M.
    Linardou, H.
    Kim, S. -W.
    Borghaei, H.
    Hellmann, M. D.
    O'Byrne, K. J.
    Paz-Ares, L. G.
    Reck, M.
    Nathan, F. E.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S3
  • [44] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
    Chau, Ian
    Doki, Yuichiro
    Ajani, Jaffer A.
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Freitas Melro Braghiroli, Maria Ignez
    Holtved, Eva
    Xynos, Ioannis
    Liu, Xuan
    Lei, Ming
    Kondo, Kaoru
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [45] Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
    Barlesi, F.
    Audigier-Valette, C.
    Felip, E.
    Ciuleanu, T-E.
    Jao, K.
    Rijavec, E.
    Urban, L.
    Aucoin, J-S.
    Zannori, C.
    Vermaelen, K.
    Aren Frontera, O.
    Ready, N.
    Curioni, A.
    Linardou, H.
    Poddubskaya, E.
    Fischer, J. R.
    Pillai, R.
    Li, S.
    Acevedo, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 33 - +
  • [46] First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
    Baas, P.
    Scherpereel, A.
    Nowak, A.
    Fujimoto, N.
    Peters, S.
    Tsao, A.
    Mansfield, A.
    Popat, S.
    Jahan, T.
    Antonia, S.
    Oulkhouir, Y.
    Bautista, Y.
    Cornelissen, R.
    Greillier, L.
    Grossi, F.
    Kowalski, D. M.
    Rodriguez-Cid, J.
    Aanur, P.
    Baudelet, C.
    Zalcman, G.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) : E42 - E42
  • [47] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
    Greil, R.
    Kato, K.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. Ignez
    Holtved, E.
    Murphy, M. Blum
    Patel, A.
    Hu, N.
    Matsumura, Y.
    Chau, I
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
  • [48] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
    Chau, Ian
    Ajani, Jaffer A.
    Kitagawa, Yuko
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Murphy, Mariela A. Blum
    Nathani, Raheel
    Hu, Nan
    Matsumura, Yasuhiro
    Kato, Ken
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
    Schenker, Michael
    Burotto, Mauricio
    Richardet, Martin
    Ciuleanu, Tudor-Eliade
    Goncalves, Anthony
    Steeghs, Neeltje
    Schoffski, Patrick
    Ascierto, Paolo A.
    Maio, Michele
    Lugowska, Iwona
    Lupinacci, Lorena
    Leary, Alexandra
    Delord, Jean-Pierre
    Grasselli, Julieta
    Tan, David S. P.
    Friedmann, Jennifer
    Vuky, Jacqueline
    Tschaika, Marina
    Konduru, Somasekhar
    Vemula, Sai Vikram
    Slepetis, Ruta
    Kollia, Georgia
    Pacius, Misena
    Duong, Quyen
    Huang, Ning
    Doshi, Parul
    Baden, Jonathan
    Di Nicola, Massimo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11
  • [50] Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
    John, T.
    Ciuleanu, T-E.
    Cobo Dols, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E. A.
    Bennouna, J.
    Cheng, Y.
    Felip, E.
    Juan Vidal, O. J.
    Alexandru, A.
    Paz-Ares, L.
    Lu, S.
    Reck, M.
    Hu, N.
    Zhang, X.
    Grootendorst, D. J.
    Eccles, L.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1034 - S1034
12345